PMID- 35184664
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20220601
IS  - 1747-4094 (Electronic)
IS  - 1747-4094 (Linking)
VI  - 15
IP  - 3
DP  - 2022 Mar
TI  - Management of relapsed or refractory large B-cell lymphoma in patients ineligible 
      for CAR-T cell therapy.
PG  - 215-232
LID - 10.1080/17474086.2022.2044778 [doi]
AB  - INTRODUCTION: Chimeric antigen receptor T (CAR-T) therapy has revolutionized the 
      treatment of relapsed/refractory large B-cell lymphoma (LBCL). However, patients 
      who are excluded or have no access to CAR-T represent a challenge for clinicians 
      and have generally a dismal outcome. The landscape for this category of patients 
      is constantly evolving: new agents have been approved in the last 2-3 years, 
      alone or in combination, and novel treatment modalities are under investigation. 
      AREAS COVERED: Thereafter, we reviewed the currently available therapeutic 
      strategies: conventional chemotherapy, antibody-drug conjugate ADC (mainly 
      polatuzumab and loncastuxumab), bispecific antibodies (CD19/CD3 and focus on 
      novel CD20/CD3 Abs), immunomodulatory drugs (covering tafasitamab and 
      lenalidomide, checkpoint inhibitors mainly in PMBL), small molecules (selinexor, 
      BTK, and PI3K inhibitors), and the role of radiotherapy. EXPERT OPINION: 
      Navigating this scenario will uncover new challenges, including identifying an 
      ideal sequence for these therapies, the most effective combinations, and search 
      for consistent predictive factors to help selecting the appropriate population of 
      LBCL patients. At present, supporting clinical research for CAR-T ineligible 
      patients, a new and challenging group, must remain a major focus that is 
      complementary to advances in CAR T-cell therapy.
FAU - Perrone, Salvatore
AU  - Perrone S
AUID- ORCID: 0000-0001-8196-0481
AD  - Hematology, Polo Universitario Pontino, S.M. Goretti Hospital, Latina, Italy.
FAU - Lopedote, Paolo
AU  - Lopedote P
AUID- ORCID: 0000-0002-7764-4336
AD  - Department of Medicine, St Elizabeth's Medical Center, Boston, Massachusetts, 
      U.S.
FAU - Levis, Mario
AU  - Levis M
AUID- ORCID: 0000-0002-7668-3296
AD  - Department of Oncology, University of Torino, Torino, Italy.
FAU - Di Rocco, Alice
AU  - Di Rocco A
AUID- ORCID: 0000-0003-0985-9623
AD  - Hematology, Department of Translational and Precision Medicine, Sapienza 
      University, Rome, Italy.
FAU - Smith, Stephen Douglas
AU  - Smith SD
AUID- ORCID: 0000-0001-5354-7593
AD  - Division of Medical Oncology, Department of Internal Medicine, University of 
      Washington, Seattle.
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle.
LA  - eng
PT  - Journal Article
DEP - 20220315
PL  - England
TA  - Expert Rev Hematol
JT  - Expert review of hematology
JID - 101485942
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Cell- and Tissue-Based Therapy
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Phosphatidylinositol 3-Kinases
MH  - *Receptors, Chimeric Antigen
OTO - NOTNLM
OT  - CAR-T cells
OT  - Diffuse large B-cell lymphoma
OT  - blinatumomab
OT  - loncastuximab tesirine
OT  - odronextamab
OT  - polatuzumab
OT  - primary mediastinal B-cell lymphoma (PMBL)
OT  - selinexor
OT  - tafasitamamb
EDAT- 2022/02/22 06:00
MHDA- 2022/04/20 06:00
CRDT- 2022/02/21 05:35
PHST- 2022/02/22 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
PHST- 2022/02/21 05:35 [entrez]
AID - 10.1080/17474086.2022.2044778 [doi]
PST - ppublish
SO  - Expert Rev Hematol. 2022 Mar;15(3):215-232. doi: 10.1080/17474086.2022.2044778. 
      Epub 2022 Mar 15.